QbD Development Process Evaluating Critical Steps

Friday, January 25, 2019   |   10:00 AM PST | 01:00 PM EST   |   Duration: 60 Minutes      


One Dial-in One Attendee

Price: US$150.00

Corporate Live

Any number of participants


Duration: 60 Minutes  


Access recorded version,
only for one participant ?

Price: US$190.00

Corporate Recorded

Access recorded version,
Any number of participants ?

Price: US$390.00

In this webinar speaker will explain - How to Build quality, safety, and efficacy into the manufacture of drug product.
Lamont M. Fulton   Product Id : 502314
  Instructor : Lamont M. Fulton

  More Trainings by this Expert


The topic of discussion focuses on practical and realistic approaches to implementation QbD, and how to apply QbD .

The selection of robust process parameters for Quality designs, and how to establish criteria to measure and discernable observances.

  • How to Build quality, safety, and efficacy into the manufacture of drug product
  • The ICH guidelines for pharmaceutical manufacturing
  • Risk-based, modern pharmaceutical manufacturing
  • Understanding Target Quality Profile, Critical Quality Attributes
  • Process parameters and design experiments
  • Regulatory concerns FDA and EMA on QbD

Why should you Attend: To establish a procedure for the proper assessment of product and process design, Also, to align evaluation of product quality standards for chemistry manufacturing and controls (CMC) review and to maintain quality standards per Office of Pharmaceutical Science (OPS)

It should be noted that OPS is responsible for assuring that the quality of drug products for the entire pharmaceutical industry follow uniform policy and review processes during drug product development (the manufacture and formulation).

Therefore, it is incumbent on all personnel involved with the preparation of documentation for subsequent submission to the regulatory authority recognize the importance of creating and maintaining a clear scientific and sound approach for all products.

Areas Covered in the Session: Quality by Design QbD formulation to manufacturing process:
  • Quality target product profile (QTPP) forms the basis for design and the development of the product. Considerations for the Quality Target Product Profile (ICH guideline Q8 R2)
  • Critical quality attributes (CQA) is a physical, chemical, biological, or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality
  • Process Analytical Technology (PAT) which is a Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance
  • Risk Assessment (RA)one can recognizing critical attributes that are going to affect final quality of product

Who Will Benefit:
  • Regulatory Affairs Directors
  • Regulatory Managers, Associates
  • Regulatory Compliance Directors, Manager
  • Technical Services Mangers
  • Plant Manager
  • Materials Management
  • Quality Control Director, Manager

Speaker Profile
Mr. Lamont Michael Fulton is President of Regulatory Direction LLc and has over Forty years of Pharmaceutical experience (26 in regulatory affairs CMC).He has had roles as both Manager and Director of Chemistry Manufacturing and Controls (CMC) Regulatory and labeling at both Branded (Merck, SmithKline, Wyeth) and Generic drugs firm (Mylan). Prior to working as the leader to regulatory affairs departments, Mr. Fulton worked at the FDA as a Chemist reviewer in the center for drugs. While at the FDA, He also worked as an Analyst in the office of regulatory affairs and international office of policy, dealing with FDA/ICH regulations and guidance for global initiatives.

Mr. Fulton's past experience in government and industry, including his current role as senior consultant, has allowed him the opportunity to develop relationship with various CMC partners (Pfizer, Johnson and Johnson, Bristol Myers Squibb, etc.). It has also afforded his consultancy the chance to assist and manage other multidisciplinary teams achieve approval for dozens of NDA's, ANDA's to the FDA, as well as provide help with several successful international drug applications to the EMEA, MHLW and ROW. The blended years of both pharmaceutical quality and regulatory affairs has provided Mr. Fulton with a perspective to determine appropriate filing strategy and provide regulatory impact of changes in post Marketing products.

Mr. Fulton has BA degree in Chemistry from Cheyney University of Pennsylvania; where he studied under Dr.Taylor on the nature of terpenes and its various derivative. Certificate of Pharmaceutical training from University of Maryland school of Pharmacy / FDA program. Mr. Fulton's affiliations included; GPhA (Generic Pharmaceutical Association), ACS American chemical society) RAP (Regulatory Affairs Professional society), PDA (Parenteral Drug Association); Sigma Xi.

Your Recently Viewed Webinars

Payment Methods

Contact Us

NetZealous LLC,
161 Mission Falls Lane, Suite 216,
Fremont, CA 94539, USA.


  Refund Policy